Citi Appointed As Depositary Bank For Abivax SA’s ADR Program

Citi has been entrusted as the depositary bank for Abivax SA’s American Depositary Receipt (ADR) program. This appointment is poised to significantly enhance the visibility and accessibility of Abivax to global investors, particularly in the United States. By facilitating Abivax’s initial public offering (IPO) on the Nasdaq Global Market, Citi underscores its commitment to expanding its comprehensive depositary receipt services. The collaboration between the two entities promises to merge Citi’s financial prowess with Abivax’s innovative approach to healthcare solutions.

Abivax, known for its innovative approach to treating chronic inflammatory diseases, will benefit from Citi’s expertise in investor relations and equity distribution, enhancing its profile in the investment community. The ADSs, each representing one ordinary share, are now trading on Nasdaq under the ticker “ABVX,” with the ordinary shares listed on Euronext Paris, signaling a new chapter in Abivax’s journey towards global market integration.

Citi’s role extends beyond the IPO, aiming to broaden Abivax’s investor outreach and provide seamless access to capital markets. With programs in 67 markets, Citi’s depositary receipt services are a testament to its global influence and operational excellence, and they stand as a pivotal resource for companies like Abivax seeking to navigate the complexities of international finance.

Citibank is a global financial services company with over 200 years of experience serving customers in more than 160 countries. With a focus on innovation and customer service, Citi offers a range of products and services, including checking accounts, credit cards, loans, and investments.